Table 2.
Treatment | Rate of IV tPA | aOR (95% CI) from model 1 | aOR (95% CI) from model 2 | aOR (95% CI) from model 3 | aOR (95% CI) from model 4 |
IV tPA among patients without contraindications | 49 456/793 175 (6.2) | ||||
Young adults | 5181/71 860 (7.2) | 1.19 (1.15 to 1.22) | 1.13 (1.10 to 1.17) | 1.20 (1.16 to 1.24) | 1.19 (1.15 to 1.22) |
Old adults | 44 275/721 315 (6.1) | 1.00 | 1.00 | 1.00 | 1.00 |
IV tPA among patients without contraindication and with onset-to-door time ≤3.5 hours | 45 842/232 905 (19.7) | ||||
Young adults | 4768/20 191 (23.6) | 1.29 (1.25 to 1.34) | 1.20 (1.15 to 1.24) | 1.24 (1.20 to 1.29) | 1.23 (1.19 to 1.28) |
Old adults | 41 074/212 714 (19.3) | 1.00 | 1.00 | 1.00 | 1.00 |
Model 1: logistic regression model without adjustment.
Model 2: adjusted for gender, insurance, BMI, previous stroke/TIA, previous CAD/prior MI, diabetes, hypertension, have smoking experience or behaviour, atrial fibrillation/flutter, glycated, haemoglobin, diastolic blood pressure, hypoglycaemic drugs, antihypertensive drugs, antiplatelet drugs, lipid-lowering drugs and hospital level.
Model 3: adjusted for were in-hospital NIHSS score, gender, insurance, BMI, previous stroke/TIA, previous CAD/prior MI, diabetes, hypertension, have smoking experience or behaviour, atrial fibrillation/flutter, glycated haemoglobin, diastolic blood pressure, hypoglycaemic drugs, antihypertensive drugs, antiplatelet drugs, lipid-lowering drugs and hospital level. Patients (n=154 052) with missing values on NIHSS score were not included in this analysis.
Model 4: results from multiple imputation.
aOR, adjusted OR; BMI, body mass index; CAD, coronary artery disease; MI, myocardial infarction; NIHSS, National Institutes of Health Stroke Scale; IV tPA, intravenous tissue plasminogen activator.